Neural and Behavioral Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA
Neural and Behavioral Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
BMJ Open. 2023 Feb 17;13(2):e067883. doi: 10.1136/bmjopen-2022-067883.
Rates of neonatal opioid withdrawal syndrome (NOWS) have paralleled the rise of opioid use during pregnancy. While short-term phenotypic symptoms of NOWS are well defined, molecular implications and long-term effects are not well understood. Preferred and first-line of treatment for NOWS includes non-pharmacological interventions; however, more than half of the NOWS neonates will need pharmacologics, with opioids as the primary pharmacological treatment. While effective at reducing symptoms, treating NOWS with opioids is paradoxical given that molecular and long-term developmental consequences with such exposure are unknown. There is a pressing need for a synthesis of current and potential/ novel treatment options for NOWS.
Following a published framework, a scoping review will be conducted to evaluate NOWS treatment, including established treatment methods and novel methods that may warrant future research and consideration. Using broad search terms, as well as Medical Subject Headings terms, a comprehensive search of PubMed, Cochrane Library, Google Scholar, CINAHL, Web of Science and Scopus, as well as references of selected literature, will take place, followed by a screening procedure to identify included and excluded articles. Included studies must address NOWS treatment, or opioid withdrawal treatment of any age group, that may or may not have been tested in preclinical or clinical models. Results will summarise the current pharmacological and non-pharmacological treatment methods for NOWS, as well as potential novel treatments with a specific interest in non-opioid pharmacological interventions.
This scoping review aims to broadly search preclinical and clinical literature as it relates to treatment of NOWS, including potential novel treatments with a specific interest in non-opioid pharmacological interventions. Given that this study does not directly involve human subjects or animal subjects research, Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC) approval is not required. Results of this scoping review will be disseminated at conferences and submitted for publication in a peer-reviewed journal.
新生儿阿片类戒断综合征(NOWS)的发生率与孕期阿片类药物使用的增加平行。虽然 NOWS 的短期表型症状定义明确,但分子影响和长期影响尚不清楚。NOWS 的首选和一线治疗包括非药物干预;然而,超过一半的 NOWS 新生儿需要药物治疗,阿片类药物是主要的药物治疗方法。虽然用阿片类药物治疗 NOWS 可以有效缓解症状,但这种治疗方法存在矛盾,因为目前还不知道这种暴露对分子和长期发育的影响。目前迫切需要对 NOWS 的现有和潜在/新型治疗选择进行综合评估。
根据已发表的框架,将进行范围综述,以评估 NOWS 的治疗方法,包括既定的治疗方法和可能需要未来研究和考虑的新型方法。将使用广泛的搜索词和医学主题词,全面搜索 PubMed、Cochrane 图书馆、Google Scholar、CINAHL、Web of Science 和 Scopus,以及选定文献的参考文献,然后进行筛选程序,以确定纳入和排除的文章。纳入的研究必须针对 NOWS 治疗,或任何年龄组的阿片类药物戒断治疗,这些治疗方法可能已经或尚未在临床前或临床模型中进行过测试。结果将总结 NOWS 的当前药理学和非药理学治疗方法,以及潜在的新型治疗方法,特别关注非阿片类药理学干预。
本范围综述旨在广泛搜索与 NOWS 治疗相关的临床前和临床文献,包括对非阿片类药理学干预有特定兴趣的潜在新型治疗方法。由于本研究不直接涉及人类受试者或动物受试者研究,因此不需要机构审查委员会(IRB)或机构动物护理和使用委员会(IACUC)的批准。本范围综述的结果将在会议上发表,并提交给同行评议期刊发表。